What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her take

Not one, not two, but three of the industry's top diabetes players last month slashed prices on their competing insulins. After Eli Lilly's cut, the strategy was quickly followed by Novo Nordisk and Sanofi, drawing praise from lawmakers and advocacy groups alike. So, what was behind the sudden change?